Eton Pharmaceuticals Gets FDA Approval of Rezipres

By Colin Kellaher

Eton Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration approved the company's Rezipres ephedrine hydrochloride injection for the treatment of clinically important hypotension occurring in the setting of anesthesia.

The Deer Park, Ill., drugmaker said Rezipres marks its second FDA-approved ready-to-use hospital injectable product.

Eton last month said the FDA had turned away its application for approval of a dehydrated alcohol injection for the treatment of methanol poisoning, saying it couldn't approve the application in its current form. Eton at the time said it believes it can address the agency's concerns in the coming months.

Trading in shares of Eton was halted Tuesday morning.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

June 15, 2021 11:05 ET (15:05 GMT)

Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From Mar 2024 to Apr 2024